Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers

Area of Science:

• Oncologic Pathology
• Molecular Diagnostics
• Neuropathology

Background:

• Advances in molecular cancer understanding and diagnostics are transforming oncologic pathology.
• Targeted therapies necessitate changes in pathology labs to guide personalized cancer treatments.

Purpose of the Study:

• To differentiate between diagnostic, predictive, and prognostic markers.
• To address challenges in translating novel biomarkers into routine clinical neuropathology practice.
• To review three predictive molecular markers for malignant gliomas.

Main Methods:

• Review of scientific literature on molecular markers in malignant gliomas.
• Analysis of operative differences between marker types.
• Discussion of practical implementation issues for laboratory use.

Main Results:

• Highlights the distinction between diagnostic, predictive, and prognostic markers.
• Focuses on 1p/19q loss, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, and EGFR-PI3K pathway alterations in gliomas.
• Identifies challenges in implementing predictive markers into routine practice.

Conclusions:

• Implementing predictive molecular markers requires critical literature review and consideration of practical, financial, and clinical management factors.
• The transition of biomarkers to routine use in neuropathology is complex.
• Careful evaluation is needed for effective integration of molecular diagnostics in glioma treatment.